Limb girdle muscular dystrophy due to sarcoglycan dysfunction, unspecified
ICD-10 G71.0340 is a billable code used to indicate a diagnosis of limb girdle muscular dystrophy due to sarcoglycan dysfunction, unspecified.
Limb girdle muscular dystrophy (LGMD) due to sarcoglycan dysfunction is a genetic disorder characterized by progressive weakness and wasting of the proximal muscles, particularly those around the hips and shoulders. This condition is caused by mutations in genes responsible for the production of sarcoglycan proteins, which are essential for muscle fiber integrity. Patients typically present with muscle weakness that may begin in childhood or adulthood, often leading to difficulty with activities such as climbing stairs, lifting objects, or running. The condition is classified under muscular dystrophies, which are a group of inherited disorders that cause muscle weakness and degeneration. Diagnosis is often confirmed through genetic testing, muscle biopsy, and clinical evaluation. As the disease progresses, individuals may experience respiratory difficulties and cardiac complications, necessitating comprehensive management strategies. The unspecified nature of this code indicates that the specific type of sarcoglycan dysfunction has not been determined, which may complicate treatment and prognosis.
Detailed neurological examination findings, muscle strength assessments, and results from genetic testing.
Patients presenting with progressive muscle weakness, difficulty in mobility, and family history of muscular dystrophy.
Ensure that all relevant diagnostic tests are documented to support the diagnosis and coding.
Genetic test results, family history, and detailed patient history regarding muscle symptoms.
Patients referred for genetic counseling after a diagnosis of muscular dystrophy.
Documentation must clearly indicate the specific genetic mutations identified.
Used when confirming a diagnosis of LGMD due to sarcoglycan dysfunction.
Documentation of clinical symptoms and family history must be included.
Neurology and genetics specialists should collaborate on documentation.
The unspecified designation indicates that the specific type of sarcoglycan dysfunction has not been identified, which may affect treatment options and prognosis.
